American Journal of Cardiology
Volume 105, Issue 1 , Pages 133-135 , 1 January 2010

Safety of Regadenoson in Patients with End-Stage Renal Disease

  • Wael Aljaroudi, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • Corresponding Author InformationCorresponding author: Tel: (205) 934-0545; fax: (205) 934-7579
    • ,
  • Daniel Hermann, MD

      Affiliations

    • Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Fadi Hage, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama
    • ,
  • Jaekyeong Heo, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Ami E. Iskandrian, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama

Received 30 June 2009 ,Revised 4 August 2009 ,Accepted 4 August 2009.

References 

  1. Iskandrian AE, Garcia EV. Nuclear cardiac imaging: principles and applications. In:  Zoghbi GJ,  Iskandrian AE editor. Pharmacological Stress Testing. 4th ed.. New York: Oxford University Press; 2008;p. 293–315
  2. Miyamoto MI, Vernotico SL, Majmundar H, Thomas GS. Pharmacologic stress myocardial perfusion imaging: a practical approach. J Nucl Cardiol. 2007;14:250–255
  3. AlJaroudi WA, Iskandrian AE. The emerging role of regadenoson, a new selective A2A adenosine receptor agonists in pharmacological stress myocardial perfusion imaging. J Am Coll Cardiol. 2009;54:1123–1130
  4. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825–833
  5. Venkataraman R, Hage FG, Dorfman T, Heo J, Aqel RA, de Mattos AM, et al. Role of myocardial perfusion imaging in patients with end-stage renal disease undergoing coronary angiography. Am J Cardiol. 2008;102:1451–1456
  6. Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, et al. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol. 2007;14:e39–e60
  7. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su KF, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med. 1995;36:2138–2147
  8. Ficaro EP, Lee BC, Kritzman JN, Corbett JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology. J Nucl Cardiol. 2007;14:455–465
  9. Iskandrian AE, Garcia EV, Faber T, Mahmarian JJ. Automated assessment of serial SPECT myocardial perfusion images. J Nucl Cardiol. 2009;16:6–9
  10. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006;45:1201–1212
  11. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14:514–520
  12. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trials. J Nucl Cardiol. 2007;14:645–658
  13. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE ADVANCE-MPI Trial investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI trial results. J Am Coll Cardiol Img. 2008;1:307–316
  14. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–776

 Dr. Iskandrian is a consultant to Gilead Sciences, Inc., Foster City, California, and to Astellas Pharma Global Development, Inc., Deerfield, Illinois.

PII: S0002-9149(09)02228-0

doi: 10.1016/j.amjcard.2009.08.663

American Journal of Cardiology
Volume 105, Issue 1 , Pages 133-135 , 1 January 2010

Article Tools

* Image Usage & Resolution